MCID: MLN008
MIFTS: 69

Melanoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Melanoma

MalaCards integrated aliases for Melanoma:

Name: Melanoma 12 25 36 29 54 6 42 43 15 37 62 39 17 71
Cutaneous Melanoma 25 29 6 17 71
Malignant Melanoma 12 25
Malignant Melanomas 15
Naevocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1909
KEGG 36 H00038
MeSH 43 D008545
NCIt 49 C3224
SNOMED-CT 67 2092003
UMLS 71 C0025202 C0151779

Summaries for Melanoma

Genetics Home Reference : 25 Melanoma is a type of skin cancer that begins in pigment-producing cells called melanocytes. This cancer typically occurs in areas that are only occasionally sun-exposed; tumors are most commonly found on the back in men and on the legs in women. Melanoma usually occurs on the skin (cutaneous melanoma), but in about 5 percent of cases it develops in melanocytes in other tissues, including the eyes (uveal melanoma) or mucous membranes that line the body's cavities, such as the moist lining of the mouth (mucosal melanoma). Melanoma can develop at any age, but it most frequently occurs in people in their fifties to seventies and is becoming more common in teenagers and young adults. Melanoma may develop from an existing mole or other normal skin growth that becomes cancerous (malignant); however, many melanomas are new growths. Melanomas often have ragged edges and an irregular shape. They can range from a few millimeters to several centimeters across. They can also be a variety of colors: brown, black, red, pink, blue, or white. Most melanomas affect only the outermost layer of skin (the epidermis). If a melanoma becomes thicker and involves multiple layers of skin, it can spread to other parts of the body (metastasize). A large number of moles or other pigmented skin growths on the body, generally more than 25, is associated with an increased risk of developing melanoma. Melanoma is also a common feature of genetic syndromes affecting the skin such as xeroderma pigmentosum. Additionally, individuals who have previously had melanoma are nearly nine times more likely than the general population to develop melanoma again. It is estimated that about 90 percent of individuals with melanoma survive at least 5 years after being diagnosed.

MalaCards based summary : Melanoma, also known as cutaneous melanoma, is related to glioma susceptibility 1 and squamous cell carcinoma, head and neck, and has symptoms including pruritus and exanthema. An important gene associated with Melanoma is MIR34A (MicroRNA 34a), and among its related pathways/superpathways are Melanoma and MicroRNAs in cancer. The drugs Vindesine and Isotretinoin have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and t cells.

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from melanocytes which are found in skin, the bowel and the eye.

MedlinePlus : 42 Melanoma is the most serious type of skin cancer. Often the first sign of melanoma is a change in the size, shape, color, or feel of a mole. Most melanomas have a black or black-blue area. Melanoma may also appear as a new mole. It may be black, abnormal, or "ugly looking." Thinking of "ABCDE" can help you remember what to watch for: Asymmetry - the shape of one half does not match the other Border - the edges are ragged, blurred or irregular Color - the color is uneven and may include shades of black, brown and tan Diameter - there is a change in size, usually an increase Evolving - the mole has changed over the past few weeks or months Surgery is the first treatment of all stages of melanoma. Other treatments include chemotherapy and radiation, biologic, and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

KEGG : 36 Melanoma is a form of skin cancer that has a poor prognosis and which is on the rise in Western populations. Melanoma arises from the malignant transformation of pigment-producing cells, melanocytes. The only known environmental risk factor is exposure to ultraviolet (UV) light and in people with fair skin the risk is greatly increased. Melanoma pathogenesis is also driven by genetic factors. Oncogenic NRAS mutations activate both effector pathways Raf-MEK-ERK and PI3K-Akt. The Raf-MEK-ERK pathway may also be activated via mutations in the BRAF gene. The PI3K-Akt pathway may be activated through loss or mutation of the inhibitory tumor suppressor gene PTEN. These mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Melanoma development has been shown to be strongly associated with inactivation of the p16INK4a/cyclin dependent kinases 4 and 6/retinoblastoma protein (p16INK4a/CDK4,6/pRb) and p14ARF/human double minute 2/p53 (p14ARF/HMD2/p53) tumor suppressor pathways. MITF and TP53 are implicated in further melanoma progression.

Novus Biologicals : 55 Melanoma is a malignant tumor that results from uncontrolled growth of pigmented cells, called melanocytes. Several types of melanoma exist, including superficial spreading melanoma, nodular melanoma and lentigo melanoma. Melanoma diagnosis is traditionally supported by the presence of the S-100 protein marker and HMB-45, however research has determined the sensitivity and specificity of three novel antibodies as markers for melanoma: Mitf, Melan-A and tyrosinase.

PubMed Health : 62 About melanoma: We all have moles or other small lumps and bumps that are a different color to the rest of our skin. This is perfectly normal and usually nothing to worry about. It is only rarely skin cancer. Skin cancer comes in different forms. The main types are (malignant) melanoma, basal cell cancer (BCC) and squamous cell cancer (SCC). Basal cell cancer and squamous cell cancer are sometimes grouped together and referred to as non-melanoma skin cancer. Melanoma, which often looks like a very dark mole, is the most widely known type of skin cancer. This is probably because some types are dangerous and can spread very quickly throughout the body.

Wikipedia : 74 Melanoma, also known as malignant melanoma, is a type of cancer that develops from the... more...

Related Diseases for Melanoma

Diseases related to Melanoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1902)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 33.3 MIR34A MIR23B MIR222 MIR221 MIR182 HOTAIR
2 squamous cell carcinoma, head and neck 33.1 SPRY4-IT1 MIR221 MIR205 HOTAIR CXCL8
3 lung cancer 32.7 STAT1 SPRY4-IT1 PVT1 MIRLET7B MIR34A MIR222
4 renal cell carcinoma, nonpapillary 32.1 STAT1 SPRY4-IT1 PVT1 MIR34A MIR23B MIR221
5 pancreatic cancer 32.0 STAT1 SPRY4-IT1 PVT1 MIR34A MIR23B MIR222
6 breast cancer 32.0 STAT1 SPRY4-IT1 PVT1 MIR34A MIR222 MIR221
7 glioma 31.8 SPRY4-IT1 PVT1 MIR34A MIR222 MIR221 HOTAIR
8 kidney cancer 31.7 PVT1 MIR532 MIR182 HOTAIR CXCL8
9 dermatomyositis 31.7 MIR34A MIR222 MIR221
10 ovarian cancer 31.7 STAT1 SPRY4-IT1 PVT1 MIRLET7B MIR532 MIR34A
11 prostate cancer 31.6 STAT1 SPRY4-IT1 PVT1 MIRLET7B MIR34A MIR23B
12 bladder cancer 31.6 SPRY4-IT1 PVT1 MIR34A MIR23B MIR222 MIR221
13 hepatocellular carcinoma 31.5 SPRY4-IT1 PVT1 MIRLET7B MIR34A MIR23B MIR222
14 thyroid cancer, nonmedullary, 1 31.5 MIR222 MIR221 LINC-ROR HOTAIR BANCR
15 leukemia, chronic lymphocytic 31.4 STAT1 MIR532 MIR34A MIR23B MIR221 MIR182
16 osteogenic sarcoma 31.4 PVT1 HOTAIR CDKN2B-AS1 BANCR
17 gastric cancer 31.4 SPRY4-IT1 PVT1 MIR34A MIR222 MIR221 LINC-ROR
18 cervical cancer 31.4 STAT1 SPRY4-IT1 PVT1 MIRLET7B MIR34A MIR23B
19 lung cancer susceptibility 3 31.4 STAT1 MIR532 MIR23B MIR205 MIR193B MIR182
20 leukemia, acute myeloid 31.4 STAT1 MIRLET7B MIR532 MIR34A MIR23B MIR222
21 esophageal cancer 31.3 PVT1 MIR34A MIR205 LINC-ROR HOTAIR CXCL8
22 oral squamous cell carcinoma 31.3 MIRLET7B MIR34A MIR23B MIR221 MIR205 HOTAIR
23 myeloma, multiple 31.3 STAT1 PVT1 MIRLET7B HOTAIR CXCL8
24 malignant glioma 31.2 SPRY4-IT1 PVT1 LINC-ROR HOTAIR CDKN2B-AS1
25 nasopharyngeal carcinoma 31.2 PVT1 MIR205 LINC-ROR HOTAIR CXCL8 CDKN2B-AS1
26 leukemia, acute lymphoblastic 31.2 MIRLET7B MIR23B MIR222 MIR221 CDKN2B-AS1
27 connective tissue disease 31.1 MIR34A MIR23B MIR222 MIR221 FBN1 CXCL8
28 pancreatic ductal adenocarcinoma 31.1 PVT1 MIR222 MIR221 MIR205 HOTAIR
29 nervous system disease 31.0 MIRLET7B MIR34A MIR23B MIR222 MIR221 MIR182
30 breast disease 31.0 MIR34A MIR222 MIR221 MIR205 MIR182
31 thyroid gland cancer 30.9 PVT1 MIR222 MIR221 MIR205 HOTAIR CDKN2B-AS1
32 polymyositis 30.9 MIR222 MIR221
33 central nervous system disease 30.8 MIRLET7B MIR34A MIR23B MIR221
34 coronary heart disease 1 30.8 MIR222 MIR221 MIR182 CDKN2B-AS1
35 hematologic cancer 30.7 PVT1 MIR532 MIR34A MIR23B MIR222 MIR221
36 thyroid gland disease 30.6 MIR23B MIR222 MIR221 MIR205
37 oral cavity cancer 30.5 MIRLET7B MIR23B MIR205 MIR193B
38 laryngeal squamous cell carcinoma 30.4 MIR34A HOTAIR CDKN2B-AS1
39 intestinal disease 30.4 MIR532 MIR34A MIR23B MIR222 MIR221 MIR205
40 gastrointestinal system disease 30.4 MIRLET7B MIR532 MIR34A MIR23B MIR222 MIR221
41 colonic disease 30.4 MIRLET7B MIR34A MIR23B MIR221 MIR182
42 facioscapulohumeral muscular dystrophy 1 30.4 MIRLET7B MIR34A MIR222 MIR221
43 gastrointestinal system cancer 30.4 MIRLET7B MIR532 MIR34A MIR23B MIR222 MIR221
44 muscular dystrophy, duchenne type 30.3 MIR34A MIR222 MIR221 MIR193B
45 stomach disease 30.3 MIR34A MIR23B MIR221 MIR182
46 melanoma, cutaneous malignant 1 12.8
47 melanoma, uveal 12.7
48 ocular melanoma 12.7
49 acral lentiginous melanoma 12.7
50 skin melanoma 12.7

Graphical network of the top 20 diseases related to Melanoma:



Diseases related to Melanoma

Symptoms & Phenotypes for Melanoma

UMLS symptoms related to Melanoma:


pruritus, exanthema

Drugs & Therapeutics for Melanoma

PubMed Health treatment related to Melanoma: 62

After melanoma is diagnosed, the first step is usually to try to remove it surgically. If it is already advanced or metastatic tumors have developed elsewhere, surgery is combined with other treatments such as medication or radiation.

Drugs for Melanoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 658)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vindesine Approved, Investigational Phase 4 53643-48-4, 59917-39-4 40839
2
Isotretinoin Approved Phase 4 4759-48-2 5538 5282379
3
Pravastatin Approved Phase 4 81093-37-0 54687
4
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
5
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
6
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
7
Citalopram Approved Phase 4 59729-33-8 2771
8
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
9
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
10
Aminolevulinic acid Approved Phase 4 106-60-5 137
11
Cabergoline Approved Phase 4 81409-90-7 54746
12
Menthol Approved Phase 4 2216-51-5 16666
13
Etanercept Approved, Investigational Phase 4 185243-69-0
14
Tofacitinib Approved, Investigational Phase 4 477600-75-2
15
Adalimumab Approved Phase 4 331731-18-1 16219006
16
ramucirumab Approved, Investigational Phase 4 947687-13-0
17
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
18
Bortezomib Approved, Investigational Phase 4 179324-69-7 387447 93860
19
Crizotinib Approved Phase 4 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
20
Palbociclib Approved, Investigational Phase 4 571190-30-2 11431660 5005498 5330286
21
Lapatinib Approved, Investigational Phase 4 231277-92-2, 388082-78-8 208908 9941095
22
Olaparib Approved Phase 4 763113-22-0 23725625
23
Ceritinib Approved Phase 4 1032900-25-6
24
Gefitinib Approved, Investigational Phase 4 184475-35-2 123631
25
Sunitinib Approved, Investigational Phase 4 341031-54-7, 557795-19-4 5329102
26
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
27
Epicatechin Investigational Phase 4 490-46-0, 35323-91-2 72276
28
Theobromine Investigational Phase 4 83-67-0 5429
29 Keratolytic Agents Phase 4
30 Salicylates Phase 4
31 Cyclosporins Phase 4
32 Psychotropic Drugs Phase 4
33 Antidepressive Agents Phase 4
34 Parasympatholytics Phase 4
35 Serotonin Agents Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Muscarinic Antagonists Phase 4
38 Cholinergic Agents Phase 4
39 Cholinergic Antagonists Phase 4
40 Viscosupplements Phase 4
41 Monoamine Oxidase Inhibitors Phase 4
42 Antiparkinson Agents Phase 4
43 Dopamine agonists Phase 4
44 Antipruritics Phase 4
45
Erlotinib Hydrochloride Phase 4 183319-69-9 176871
46 Protein Kinase Inhibitors Phase 4
47
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
48
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
49
Timolol Approved Phase 3 26839-75-8 33624 5478
50
Ethanol Approved Phase 2, Phase 3 64-17-5 702

Interventional clinical trials:

(show top 50) (show all 2935)
# Name Status NCT ID Phase Drugs
1 Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma Unknown status NCT00226473 Phase 4 Cisplatin, Vindesine, Dacarbazine (drugs)
2 Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies Unknown status NCT02626065 Phase 4 Nivolumab
3 A Randomized Control Trial of Intravitreal Ranibizumab (Lucentis) for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy for Choroidal Melanoma Unknown status NCT00540930 Phase 4 Ranibizumab
4 Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy Unknown status NCT02379000 Phase 4 Triamcinolone Acetonide
5 Randomized Controlled Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer Unknown status NCT01038154 Phase 4 Pravastatin
6 Clinical, Laboratorial and Quality of Life Trial to Evaluate the Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea. Unknown status NCT01139749 Phase 4 oral isotretinoin;salicylic acid and ciclopirox olamine
7 An Open-Label, Single-Arm, Multicenter Study To Assess The Safety Of Vemurafenib In Patients With Braf V600 Mutation Positive Metastatic Melanoma In South Africa. Completed NCT01898585 Phase 4 Zelboraf
8 Can Fibrin Sealant be Used to Reduce Post-operative Drainage Following Lymph Node Dissection: a Prospective Randomised Double Blind Trial. Completed NCT00324272 Phase 4 Fibrin Sealant (Tisseel) used in the Experimental Arm.
9 Can We Miss Pigmented Lesions in Psoriasis Patients? Completed NCT01053819 Phase 4 etanercept
10 An Evaluation of the Efficacy of the Tumor Necrosis Factor-alpha Antagonist Infliximab in Treatment Resistant Major Depression: Mechanisms and Mediators Completed NCT00463580 Phase 4 Infliximab;Placebo
11 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
12 A Randomized Control Trial for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection Completed NCT02476357 Phase 4
13 IL-2 Neuropsychiatric Symptoms: Mechanism and Prevention Completed NCT00352885 Phase 4 Escitalopram;Placebo;IL-2
14 Photodynamic Therapy for Melanoma Precursor Lesion Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion (BF-200 ALA) as a Light Sensitizing Cream Completed NCT02685592 Phase 4 5-aminolevulinic acid nanoemulsion
15 An Open-Label Study Using the MedPulser Electroporation System to Treat Cutaneous and Subcutaneous Foci of Cancer Completed NCT00198276 Phase 4
16 Prospective, Controlled and Monocentric Study to Evaluate the Effects of Topical 3% Diclofenac in 2.5% Hyaluronic Acid Gel on Tumor Metabolism in the Treatment of Actinic Keratoses in Immunocompetent and Immunocompromised Patients Completed NCT01935531 Phase 4 3% diclofenac in 2.5% hyaluronic acid gel
17 Treatment of AKs With Daylight-PDT: Comparing Two Photosensitizers (BF-200 ALA and MAL) Completed NCT01893203 Phase 4 BF-200 ALA cream;MAL cream
18 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
19 Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease. Completed NCT00640159 Phase 4 Zelapar
20 A Comparison of Polyglactin 910 and Chromic Gut Suture in the Closure of Punch Biopsy Sites Completed NCT01722994 Phase 4
21 Neoadjuvant GM-CSF Treatment and Modulation of Immune Cell Profile of the SLN in Melanoma Recruiting NCT02451488 Phase 4 GM-CSF
22 Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study Recruiting NCT03340506 Phase 4 dabrafenib;trametinib
23 A Prospective, Open-label, Phase 4 Study to Evaluate the Safety of Pembrolizumab (KEYTRUDA®) in Subjects With Unresectable or Metastatic Melanoma or PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) in India (Keynote-593) Recruiting NCT03715205 Phase 4 Pembrolizumab
24 Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial Recruiting NCT03673332 Phase 4 immune-checkpoint inhibitors therapies
25 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
26 A Randomised Double Blind, Placebo Controlled Study of the Efficacy of Topical Menthol for Pain Relief During Topical Photodynamic Therapy Recruiting NCT02984072 Phase 4 Menthol;Aqueous Cream
27 Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial Recruiting NCT03909646 Phase 4 Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram;5Fluorouracil
28 Phase IV Ipilimumab in Melanoma: A National, Multicenter, Interventional Study in Patients With Unresectable or Metastatic Melanoma Active, not recruiting NCT02068196 Phase 4 Ipilimumab
29 PHASE 3B/4 RANDOMIZED SAFETY ENDPOINT STUDY OF 2 DOSES OF TOFACITINIB IN COMPARISON TO A TUMOR NECROSIS FACTOR (TNF) INHIBITOR IN SUBJECTS WITH RHEUMATOID ARTHRITIS Active, not recruiting NCT02092467 Phase 4 tofacitinib;tofacitinib
30 COcoa Supplement and Multivitamin Outcomes Study Active, not recruiting NCT02422745 Phase 4
31 Influenza Vaccine Responses in the Setting of Melanoma Treatment Enrolling by invitation NCT03315975 Phase 4
32 Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma Not yet recruiting NCT02645149 Phase 4 Standard therapy or clinical trial;Matched targeted therapy;Trametinib and / or supportive care
33 Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting Programmed Cell Death 1 (PD-1) Not yet recruiting NCT03313544 Phase 4 Nivolumab
34 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
35 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
36 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
37 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
38 A Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Plus BCG Versus Placebo Plus BCG as a Post-Surgical Treatment for Stage IV Melanoma Unknown status NCT00052156 Phase 3
39 Phase III Randomized Double-Blind Pivotal Trial of Immunotherapy With BCG Plus a Polyvalent Melanoma Vaccine, CancerVax™ Vaccine Versus BCG Plus a Placebo as a Post-Surgical Treatment for Stage III Melanoma Unknown status NCT00052130 Phase 3
40 Randomized, Comparative Phase II/III Study Between Treatment With CSF470 Vaccine (Allogeneic, Irradiated) Plus BCG and MOLGRAMOSTIN (rhGM-CSF) as Adjuvants and Interferon-alfa 2b (IFN-ALPHA), in Stages IIB, IIC and III Post Surgery Cutaneous Melanoma Patients Unknown status NCT01729663 Phase 2, Phase 3 interferon alpha 2b
41 Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination: Post-Operative Adjuvant Ganglioside GM2-KLH/QS-21 (BMS-248479) Vaccination Treatment After Resection of Primary Cutaneous Melanoma Thicker Than 1.5mm (AJCC/UICC Stage II, T3-T4N0M0), a 2-Arm Multicenter Randomized Phase III Trial vs. Observation Unknown status NCT00005052 Phase 3
42 A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma Patients Unknown status NCT02938299 Phase 3 L19IL2 + L19TNF
43 PHASE III TRIAL OF MELACINE PLUS INTERFERON ALFA-2B VERSUS INTERFERON ALFA-2B IN PATIENTS WITH DISSEMINATED MALIGNANT MELANOMA Unknown status NCT00002767 Phase 3
44 Randomized, Multicenter Study for Adjuvant Treatment of Stage III Malignant Melanoma: Intermittent, High-Dose Intravenous Interferon Alpha-2b Versus Standard High-Dose Interferon Alpha-2b Therapy Unknown status NCT00226408 Phase 3 Interferon-alpha-2b
45 A Phase III, Multi-Center Controlled Trial With Stratified Randomization Comparing The Efficacy Of Interleukin-2 (IL-2) Plus Histamine Dihydrochloride (HDC) Versus IL-2 Alone To Increase The Duration Of Survival In Patients With AJCC Stage IV Malignant Melanoma With Hepatic Metastasis Unknown status NCT00039234 Phase 3 histamine dihydrochloride
46 A Randomized, Open and Control Clinical Study of Endostar Injection Concomitant With SOX Protocols in Treating Advanced Gastric Cancer Unknown status NCT02008422 Phase 3 Oxaliplatin;Gimeracil and Oteracil Potassium Capsule;Endostar injection
47 Immunotherapy of Colon Cancer With Autologous Perchloric Soluble Tumors Extracts Unknown status NCT00002455 Phase 3
48 Treatment Of Radiation Retinopathy Trial Subtitle: Treatment of Radiation Retinopathy; Influence of Lucentis® and Kenalog® on Radiation Retinopathy After Irradiation of Choroidal Melanoma. Unknown status NCT00811200 Phase 2, Phase 3 ranibizumab;triamcinolone acetonide
49 POST-OPERATIVE ADJUVANT INTERFERON-ALFA-2B (INTRON-A) TREATMENT AFTER RESECTION OF THICK PRIMARY MELANOMA AND/OR REGIONAL LYMPHNODE METASTASES 'INTERMEDIATE-HIGH DOSE' VS INTERMEDIATE-LOW DOSE' IFN-ALFA VS OBSERVATION: A 3-ARM MULTICENTER RANDOMIZED PHASE III TRIAL Unknown status NCT00002763 Phase 3
50 Allogeneic Vaccine Modified to Express HLA A2/4-1BB Ligand for High Risk or Low Residual Disease Melanoma Patients Unknown status NCT01861938 Phase 2, Phase 3

Search NIH Clinical Center for Melanoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Aldesleukin
Carmustine
dabrafenib
Dacarbazine
docetaxel
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
peginterferon alfa-2a
peginterferon alfa-2b
pembrolizumab
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
temozolomide
trametinib
Vemurafenib

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Melanoma cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Melanoma:
Tumor infiltrating lymphocytes (TILs) for solid tumors
Embryonic/Adult Cultured Cells Related to Melanoma:
Tumor infiltrating lymphocytes PMIDs: 24329789 19342963 21498393 22996367 19304471 22555974 15800326 23650429 21325070 8170938 12242449 24218514 23904171

Cochrane evidence based reviews: melanoma

Genetic Tests for Melanoma

Genetic tests related to Melanoma:

# Genetic test Affiliating Genes
1 Cutaneous Melanoma 29
2 Melanoma 29

Anatomical Context for Melanoma

MalaCards organs/tissues related to Melanoma:

40
Skin, Lymph Node, T Cells, Brain, Lung, Breast, Liver

Publications for Melanoma

Articles related to Melanoma:

(show top 50) (show all 38547)
# Title Authors PMID Year
1
MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. 54 61 46
20304954 2010
2
MicroRNA-dependent regulation of cKit in cutaneous melanoma. 54 61 46
19126397 2009
3
Surgical Management of Primary Cutaneous Melanoma. 61 42
31753116 2020
4
Surgical Management of Lymph Nodes in Melanoma. 61 42
31753117 2020
5
Nonsurgical Management of Lymph Node Basins in Melanoma. 61 42
31753118 2020
6
MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. 61 46
20357817 2010
7
Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. 61 46
19336521 2009
8
MicroRNA-221 and -222 pathway controls melanoma progression. 61 46
18983236 2008
9
MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. 54 46
18379589 2008
10
The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. 61 46
18417445 2008
11
A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma. 46
21119596 2011
12
Co-regulated expression of matrix metalloproteinase-2 and transforming growth factor-beta in melanoma development and progression. 54 61
20514447 2010
13
S100A13 is a new angiogenic marker in human melanoma. 54 61
20208480 2010
14
Macrophage inhibitory cytokine-1 regulates melanoma vascular development. 54 61
20431030 2010
15
MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. 46
19830692 2010
16
Serum markers of cutaneous melanoma. 54 61
20515782 2010
17
Fascin, cortactin and survivin expression of melanocytic neoplasms and association with clinicopathological parameters and anatomic locations in Chinese people. 54 61
20400386 2010
18
Chemokine-chemokine receptor axes in melanoma brain metastasis. 54 61
20005902 2010
19
Signatures of microRNAs and selected microRNA target genes in human melanoma. 46
20442294 2010
20
Mutation-driven drug development in melanoma. 54 61
20401974 2010
21
Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. 54 61
20179267 2010
22
Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure. 54 61
20088873 2010
23
Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. 54 61
20482674 2010
24
PAX3 and SOX10 activate MET receptor expression in melanoma. 54 61
20067553 2010
25
Roles of endothelin signaling in melanocyte development and melanoma. 54 61
20128875 2010
26
Purification and N-glycosylation analysis of melanoma antigen dopachrome tautomerase. 54 61
20386969 2010
27
Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. 54 61
20230195 2010
28
Pharmacodynamic (phase 0) study using etaracizumab in advanced melanoma. 54 61
20445352 2010
29
Lysyl oxidase expression and inhibition in uveal melanoma. 54 61
20179655 2010
30
Constitutive HIF-1 activity in malignant melanoma. 54 61
20185296 2010
31
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. 54 61
20173664 2010
32
MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells. 54 61
20098411 2010
33
Overcoming immunological tolerance to melanoma: Targeting CTLA-4. 54 61
20482528 2010
34
Distinct MHC gene expression patterns during progression of melanoma. 54 61
19862823 2010
35
TYRO3-mediated regulation of MITF: a novel target in melanoma? 54 61
19843245 2010
36
Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. 54 61
19788535 2010
37
Fluvastatin increases tyrosinase synthesis induced by alpha-melanocyte-stimulating hormone in B16F10 melanoma cells. 54 61
20360626 2010
38
Patterns of GRP78 and MTJ1 expression in primary cutaneous malignant melanoma. 54 61
19838160 2010
39
The association between MC1R genotype and BRAF mutation status in cutaneous melanoma: findings from an Australian population. 54 61
19571821 2010
40
Tanning beds, skin cancer, and vitamin D: An examination of the scientific evidence and public health implications. 54 61
20136909 2010
41
Expression and function of CD9 in melanoma cells. 54 61
19777564 2010
42
Role of erythropoietin receptor expression in malignant melanoma. 54 61
19536148 2010
43
Identification of melanoma antigens using a Serological Proteome Approach (SERPA). 54 61
20181627 2010
44
Modulation of T-cell activation by malignant melanoma initiating cells. 54 61
20068175 2010
45
CXCL8 and its cognate receptors in melanoma progression and metastasis. 54 61
20021212 2010
46
E2F1 in melanoma progression and metastasis. 54 61
20026813 2010
47
KIT as a therapeutic target in melanoma. 54 61
19847190 2010
48
Prognostic relevance of hypoxia inducible factor-1alpha expression in patients with melanoma. 54 61
20055873 2009
49
A predicted functional single-nucleotide polymorphism of bone morphogenetic protein-4 gene affects mRNA expression and shows a significant association with cutaneous melanoma in Southern Italian population. 54 61
19557432 2009
50
SKI knockdown inhibits human melanoma tumor growth in vivo. 54 61
19845874 2009

Variations for Melanoma

ClinVar genetic disease variations for Melanoma:

6 ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FBN1 NM_000138.4(FBN1):c.5788+5G>ASNV Pathogenic 42394 rs193922219 15:48738898-48738898 15:48446701-48446701
2 CDKN2A NM_000077.4(CDKN2A):c.197A>C (p.His66Pro)SNV Uncertain significance 419802 rs756750256 9:21971161-21971161 9:21971162-21971162
3 BRCA2 NM_000059.3(BRCA2):c.2063A>G (p.Tyr688Cys)SNV Uncertain significance 523315 rs28897713 13:32910555-32910555 13:32336418-32336418

Cosmic variations for Melanoma:

9 (show top 50) (show all 1725)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM96846998 PTEN skin,lower leg,malignant melanoma,superficial spreading c.737C>T p.P246L 10:87957955-87957955 24
2 COSM88585287 PREX2 skin,lower leg,malignant melanoma,superficial spreading c.4646C>T p.A1549V 8:68217657-68217657 24
3 COSM88577133 PREX2 skin,lower leg,malignant melanoma,superficial spreading c.34G>T p.E12* 8:67952428-67952428 24
4 COSM88595561 PREX2 skin,back,malignant melanoma,superficial spreading c.4165G>A p.E1389K 8:68146286-68146286 24
5 COSM88584890 PREX2 skin,lower leg,malignant melanoma,nodular c.2323C>T p.P775S 8:68093677-68093677 24
6 COSM88571924 PREX2 skin,lower leg,malignant melanoma,nodular c.4127C>T p.A1376V 8:68146248-68146248 24
7 COSM88574860 PREX2 skin,back,malignant melanoma,superficial spreading c.2531G>A p.G844D 8:68097179-68097179 24
8 COSM97114616 NRAS skin,lower leg,malignant melanoma,nodular c.181C>G p.Q61E 1:114713909-114713909 24
9 COSM93672521 NF1 skin,back,malignant melanoma,nodular c.3028C>T p.Q1010* 17:31230297-31230297 24
10 COSM85270786 MLH1 skin,lower leg,malignant melanoma,nodular c.1732-1G>A p.? 3:37047518-37047518 24
11 COSM150563774 BRAF skin,back,malignant melanoma,superficial spreading c.1799T>A p.V600E 7:140753336-140753336 24
12 COSM150585368 BRAF skin,back,malignant melanoma,superficial spreading c.1790T>G p.L597R 7:140753345-140753345 24
13 COSM150623748 BRAF skin,back,malignant melanoma,nodular c.1784T>C p.F595S 7:140753351-140753351 24
14 COSM150645318 BRAF skin,back,malignant melanoma,superficial spreading c.1814G>A p.S605N 7:140753321-140753321 24
15 COSM88872369 APC skin,lower leg,malignant melanoma,superficial spreading c.4431G>T p.Q1477H 5:112840025-112840025 24
16 COSM149414187 skin,lower leg,malignant melanoma,superficial spreading c.1869T>C p.F623= 7:140753386-140753386 24
17 COSM91859752 skin,back,malignant melanoma,superficial spreading c.35G>T p.G12V 12:25245350-25245350 24
18 COSM88834639 skin,back,malignant melanoma,superficial spreading c.1910T>G p.L637R 7:140753345-140753345 24
19 COSM149460904 skin,back,malignant melanoma,nodular c.1904T>C p.F635S 7:140753351-140753351 24
20 COSM114526600 skin,lower leg,malignant melanoma,nodular c.1009-1G>A p.? 3:37047518-37047518 24
21 COSM130661839 skin,lower leg,malignant melanoma,nodular c.1009-1G>A p.? 3:37047518-37047518 24
22 COSM118886840 skin,back,malignant melanoma,superficial spreading c.1814G>A p.S605N 7:140753321-140753321 24
23 COSM134990158 skin,back,malignant melanoma,superficial spreading c.35G>T p.G12V 12:25245350-25245350 24
24 COSM122387386 skin,lower leg,malignant melanoma,superficial spreading c.4431G>T p.Q1477H 5:112840025-112840025 24
25 COSM118818356 skin,back,malignant melanoma,superficial spreading c.1817G>A p.G606E 7:140753318-140753318 24
26 COSM113092596 skin,lower leg,malignant melanoma,nodular c.1009-1G>A p.? 3:37047518-37047518 24
27 COSM149491596 skin,back,malignant melanoma,superficial spreading c.1934G>A p.S645N 7:140753321-140753321 24
28 COSM149420177 skin,back,malignant melanoma,superficial spreading c.1937G>A p.G646E 7:140753318-140753318 24
29 COSM130952662 skin,lower leg,malignant melanoma,nodular c.1009-1G>A p.? 3:37047518-37047518 24
30 COSM108957066 skin,lower leg,malignant melanoma,nodular c.1438-1G>A p.? 3:37047518-37047518 24
31 COSM93525440 skin,back,malignant melanoma,nodular c.3028C>T p.Q1010* 17:31230297-31230297 24
32 COSM149265690 ZFHX3 skin,mucosal,malignant melanoma,NS c.1064C>T p.A355V 16:72959082-72959082 18
33 COSM91367549 WT1 skin,lower leg,malignant melanoma,NS c.1373G>A p.R458Q 11:32392031-32392031 18
34 COSM85729105 TSC1 skin,mucosal,malignant melanoma,NS c.2281T>C p.Y761H 9:132902715-132902715 18
35 COSM85729050 TSC1 skin,mucosal,malignant melanoma,NS c.587C>A p.P196H 9:132921895-132921895 18
36 COSM85729137 TSC1 skin,mucosal,malignant melanoma,NS c.1598C>A p.P533H 9:132905980-132905980 18
37 COSM85729097 TSC1 skin,mucosal,malignant melanoma,NS c.2102A>G p.Q701R 9:132903757-132903757 18
38 COSM85729091 TSC1 skin,mucosal,malignant melanoma,NS c.1375C>G p.L459V 9:132906794-132906794 18
39 COSM85729074 TSC1 skin,mucosal,malignant melanoma,NS c.2541C>A p.F847L 9:132900799-132900799 18
40 COSM85729132 TSC1 skin,mucosal,malignant melanoma,NS c.322T>C p.S108P 9:132925628-132925628 18
41 COSM85729114 TSC1 skin,mucosal,malignant melanoma,NS c.2974A>G p.R992G 9:132897185-132897185 18
42 COSM85729150 TSC1 skin,mucosal,malignant melanoma,NS c.2518T>A p.S840T 9:132900822-132900822 18
43 COSM85719726 TSC1 skin,mucosal,malignant melanoma,NS c.323C>T p.S108F 9:132925627-132925627 18
44 COSM94305313 TRRAP skin,lower leg,malignant melanoma,NS c.2165C>T p.S722F 7:98912179-98912179 18
45 COSM84317094 TRAF2 skin,mucosal,malignant melanoma,NS c.923G>A p.R308Q 9:136920478-136920478 18
46 COSM87898714 TP53 skin,mucosal,malignant melanoma,NS c.844C>T p.R282W 17:7673776-7673776 18
47 COSM87898709 TP53 skin,NS,malignant melanoma,superficial spreading c.742C>T p.R248W 17:7674221-7674221 18
48 COSM87933590 TP53 skin,mucosal,malignant melanoma,NS c.524G>T p.R175L 17:7675088-7675088 18
49 COSM87899661 TP53 skin,NS,malignant melanoma,nodular c.797G>A p.G266E 17:7673823-7673823 18
50 COSM87904406 TP53 skin,mucosal,malignant melanoma,NS c.796G>A p.G266R 17:7673824-7673824 18

Copy number variations for Melanoma from CNVD:

7 (show top 50) (show all 1973)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13791 1 1 46500000 Insertion Melanoma
2 13897 1 1007060 1041599 Amplification C1orf159 Melanoma
3 14968 1 111600000 148000000 Deletion Melanoma
4 15008 1 111800000 116100000 Gain NRAS Melanoma
5 15387 1 115048600 115061038 Gain NRAS Melanoma
6 18715 1 147200000 149200000 Ampfication SETDB1 Melanoma
7 20086 1 15300000 247249719 Insertion Melanoma
8 21281 7 92072170 92303813 Gain CDK6 Malignant melanoma
9 24543 1 182188599 196365692 Amplification ASPM Melanoma
10 24544 1 182188599 196365692 Amplification ATP6V1G3 Melanoma
11 24545 1 182188599 196365692 Amplification B3GALT2 Melanoma
12 24546 1 182188599 196365692 Amplification C1orf27 Melanoma
13 24547 1 182188599 196365692 Amplification C1orf53 Melanoma
14 24548 1 182188599 196365692 Amplification C1orf99 Melanoma
15 24549 1 182188599 196365692 Amplification CDC73 Melanoma
16 24550 1 182188599 196365692 Amplification CFH Melanoma
17 24551 1 182188599 196365692 Amplification CFHR1 Melanoma
18 24552 1 182188599 196365692 Amplification CFHR2 Melanoma
19 24553 1 182188599 196365692 Amplification CFHR3 Melanoma
20 24554 1 182188599 196365692 Amplification CFHR4 Melanoma
21 24555 1 182188599 196365692 Amplification CFHR5 Melanoma
22 24556 1 182188599 196365692 Amplification CRB1 Melanoma
23 24557 1 182188599 196365692 Amplification DENND1B Melanoma
24 24558 1 182188599 196365692 Amplification F13B Melanoma
25 24559 1 182188599 196365692 Amplification FAM5C Melanoma
26 24560 1 182188599 196365692 Amplification GLRX2 Melanoma
27 24561 1 182188599 196365692 Amplification HMCN1 Melanoma
28 24562 1 182188599 196365692 Amplification KCNT2 Melanoma
29 24563 1 182188599 196365692 Amplification LHX9 Melanoma
30 24564 1 182188599 196365692 Amplification NEK7 Melanoma
31 24565 1 182188599 196365692 Amplification OCLM Melanoma
32 24566 1 182188599 196365692 Amplification PDC Melanoma
33 24567 1 182188599 196365692 Amplification PLA2G4A Melanoma
34 24568 1 182188599 196365692 Amplification PRG4 Melanoma
35 24569 1 182188599 196365692 Amplification PTGS2 Melanoma
36 24570 1 182188599 196365692 Amplification PTPRC Melanoma
37 24571 1 182188599 196365692 Amplification RGS1 Melanoma
38 24572 1 182188599 196365692 Amplification RGS13 Melanoma
39 24573 1 182188599 196365692 Amplification RGS18 Melanoma
40 24574 1 182188599 196365692 Amplification RGS2 Melanoma
41 24575 1 182188599 196365692 Amplification RGS21 Melanoma
42 24576 1 182188599 196365692 Amplification TPR Melanoma
43 24577 1 182188599 196365692 Amplification TROVE2 Melanoma
44 24578 1 182188599 196365692 Amplification UCHL5 Melanoma
45 24579 1 182188599 196365692 Amplification ZBTB41 Melanoma
46 26238 1 198304656 198310281 Deletion Melanoma
47 29172 1 228366540 228914590 LOH Melanoma
48 29295 1 2300000 46500000 Insertion Melanoma
49 29296 1 2300000 46500000 Insertion Melanoma
50 30306 1 241700000 247249719 Insertion Melanoma

Expression for Melanoma

Search GEO for disease gene expression data for Melanoma.

Pathways for Melanoma

Pathways related to Melanoma according to KEGG:

36
# Name Kegg Source Accession
1 Melanoma hsa05218

Pathways related to Melanoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.66 MIRLET7B MIR34A MIR23B MIR222 MIR221 MIR205
2 10.83 MIR23B MIR222 MIR221
3 10.23 LINC-ROR HOTAIR

GO Terms for Melanoma

Cellular components related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.28 MIRLET7B MIR532 MIR222 MIR221 MIR205 MIR182

Biological processes related to Melanoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.8 MIRLET7B MIR23B MIR222 MIR221
2 negative regulation of inflammatory response GO:0050728 9.73 MIR222 MIR221 MIR205
3 negative regulation of angiogenesis GO:0016525 9.71 STAT1 MIR34A MIR222
4 negative regulation of sprouting angiogenesis GO:1903671 9.61 MIR34A MIR23B MIR221
5 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.58 MIRLET7B MIR23B
6 negative regulation of cytokine production involved in inflammatory response GO:1900016 9.57 MIR222 MIR221
7 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.55 MIR34A MIR182
8 positive regulation of axon regeneration GO:0048680 9.52 MIR222 MIR221
9 negative regulation by host of viral genome replication GO:0044828 9.51 MIR222 MIR221
10 positive regulation of erythrocyte differentiation GO:0045648 9.5 STAT1 MIR222 MIR221
11 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.48 MIR222 MIR221
12 negative regulation of cell adhesion molecule production GO:0060354 9.46 MIR222 MIR221
13 negative regulation of TRAIL-activated apoptotic signaling pathway GO:1903122 9.4 MIR222 MIR221
14 positive regulation of Schwann cell migration GO:1900149 9.37 MIR222 MIR221
15 positive regulation of Schwann cell proliferation involved in axon regeneration GO:1905046 9.26 MIR222 MIR221
16 miRNA mediated inhibition of translation GO:0035278 9.26 MIR222 MIR221 MIR205 MIR182
17 gene silencing by miRNA GO:0035195 9.23 MIRLET7B MIR34A MIR23B MIR222 MIR221 MIR205
18 negative regulation of hematopoietic stem cell proliferation GO:1902034 9.16 MIR222 MIR221

Molecular functions related to Melanoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIRLET7B MIR34A MIR23B MIR222 MIR221 MIR205

Sources for Melanoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....